Researchers from Zhuhai Grit Biotechnology Co. Ltd. recently presented preclinical characterization of a new genetically modified tumor-infiltrating lymphocyte (TIL) product, GT-216, being developed for the treatment of solid tumors.
CD276-based immunotherapy strategies have demonstrated potent antitumor activity and feasibility for clinical application in solid tumors. In urothelial bladder cancer, CD276 is also aberrantly expressed. However, the exact role of CD276 in bladder cancer tumorigenesis and its potential clinical significance remain unexplored.
Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.
The leukocyte immunoglobulin-like receptor B2 (LILRB2), also known as ILT4, is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor that is widely expressed on immunosuppressive myeloid cells in the tumor microenvironment.
Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
A research team at University of California, Los Angeles (UCLA), funded by Cancervax Inc., has created a promising new bispecific antibody vaccine for treating recurrent Ewing sarcoma.
Researchers from Abbvie Inc. recently presented preclinical data for ABBV-706, an SEZ6-targeted topoisomerase 1 (TOP1) inhibitor antibody-drug conjugate (ADC), being developed for the treatment of small-cell lung cancer (SCLC) and other SEZ6-expressing cancers.
Proviva Therapeutics Ltd. scientists hypothesized that both the activation of IL-2 receptor (IL-2R) and the blockade of programmed cell death protein 1 (PD-1) are complementary and potentially synergistic as a combination therapy for treating cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies covalently linked to TLR7 and/or TLR8 agonists through cleavable or uncleavable linkers.
RSS
.webp?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
